Reference number(s)
6242-A

Standard Medicare Part B Management Omvoh Intravenous (IV)

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name	Dosage Form
Omvoh	mirikizumab-mrkz	intravenous (IV)

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met, the member has no exclusions to the prescribed therapy, and the drug or biological is usually not self-administered. The criteria outlined in this policy is only applicable to drugs not usually self-administered and are furnished incident to a physician's service. Requests for drugs on a region's self-administered drug list are not covered. Members enrolled in Medicare Part D may seek coverage under their Medicare Part D plan.

FDA-approved Indications[1]

- Treatment of moderately to severely active ulcerative colitis in adults.
- Treatment of moderately to severely active Crohn's disease in adults.

All other indications will be assessed on an individual basis. Submissions for indications other than those listed in this criteria should be accompanied by supporting evidence from Medicare approved compendia.

© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Reference number(s)
6242-A

Coverage Criteria

Ulcerative colitis (UC)[1]

Authorization of 12 months may be granted for treatment of moderately to severely active ulcerative colitis.

Crohn's disease (CD)[1]

Authorization of 12 months may be granted for treatment of moderately to severely active Crohn's disease.

Summary of Evidence

The contents of this policy were created after examining the following resources:

- The prescribing information for Omvoh.
- The available compendium:
    - National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium
    - Micromedex DrugDex
    - American Hospital Formulary Service- Drug Information (AHFS-DI)
    - Lexi-Drugs
    - Clinical Pharmacology
- American College of Gastroenterology (ACG) Clinical Guideline: Ulcerative Colitis in Adults
- American Gastroenterological Association (AGA) Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis
- ACG Clinical Guideline: Management of Crohn's Disease in Adults
- AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease

After reviewing the information in the above resources, the FDA-approved indications listed in the prescribing information for Omvoh are covered.

Explanation of Rationale

Support for FDA-approved indications can be found in the manufacturer's prescribing information.

References

1. Omvoh [package insert]. Indianapolis, IN: Eli Lilly and Company.; January 2025.

© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

2. Self-Administered Drug Exclusion List: and Biologicals Excluded from Coverage- Medical Policy Article (A52527) Version R57. Available at: https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx. Accessed January 22, 2025.
3. Self-Administered Drug Exclusion List: (A52571) Version 27. Available at: https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx. Accessed January 22, 2025.
4. Self-Administered Drug Exclusion List: (A53032) Version R40. Available at: https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx. Accessed January 22, 2025.
5. Self-Administered Drug Exclusion List: (A53033) Version R41. Available at: https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx. Accessed January 22, 2025.
6. Self-Administered Drug Exclusion List: Medical Policy Article (A53021) Version R40. Available at: https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx. Accessed January 22, 2025.
7. Self-Administered Drug Exclusion List: (SAD List) (A52800) Version R37. Available at: https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx. Accessed January 22, 2025.
8. Self-Administered Drug Exclusion List: (A53127) Version R25. Available at: https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx. Accessed January 22, 2025.
9. Self-Administered Drug Exclusion List: (A53066) Version R46. Available at: https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx. Accessed January 22, 2025.
10. Self-Administered Drug Exclusion List: Medical Policy Article (A53022) Version R38. Available at: https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx. Accessed January 22, 2025.

© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.